CLINICAL_TRIALS trial_result · 2025-06-17

Clinical Trial Update: A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma [Phase 1]

Phase 1 study of AMG 340 in metastatic castration-resistant prostate cancer was terminated. Results were posted on 2025-06-17.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Amgen | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 1 | Status: TERMINATED | Results posted: 2025-06-17